Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 9/20 | 0.41 |
| ▸ | MAOA | P21397 | 8/20 | 0.41 |
| ▸ | MAOB | P27338 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28766998 | 0.81 | SLC18A3 (0.55) | TSHRTRPA1SLC18A3KDM1AMAOA | |
| SCHEMBL1535881 | 0.79 | SLC6A9 (0.43) | TSHRTRPA1SLC18A3MEN1KMT2A | |
| SCHEMBL8720460 | 0.79 | KDM1A (0.42) | TSHRTRPA1SLC18A3KDM1AMAOA | |
| SCHEMBL23646574 | 0.78 | AKR1C1 (0.42) | TSHRTRPA1SLC18A3MEN1KMT2A | |
| SCHEMBL151522 | 0.78 | TSHR (0.41) | TSHRTRPA1SLC18A3ALDH1A1GAA | |
| SCHEMBL9508537 | 0.78 | TSHR (0.41) | TSHRTRPA1SLC18A3MEN1KMT2A | |
| SCHEMBL4989697 | 0.77 | KDM1A (0.45) | TSHRTRPA1SLC18A3KDM1AMAOA | |
| SCHEMBL1033763 | 0.77 | TSHR (0.40) | TSHRTRPA1SLC18A3KDM1AMAOA | |
| SCHEMBL29895223 | 0.77 | TSHR (0.40) | TSHRTRPA1SLC18A3MEN1KMT2A | |
| SCHEMBL11476007 | 0.77 | TRPA1 (0.41) | TSHRTRPA1SLC18A3KDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11030588-A | — | — | None | — | — | JP | disclosed |
| CN-112898738-B | Epoxy resin composition, prepreg, laminate, printed wiring board, and cured product using same | 日铁化学材料株式会社 | 2024-03-22 | — | — | CN | disclosed |
| US-11926605-B2 | Functionalized bifuran and synthesis thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2024-03-12 | — | — | US | disclosed |
| CN-112898738-A | Epoxy resin composition, prepreg, laminate, printed wiring board, and cured product using same | 日铁化学材料株式会社 | 2021-06-04 | — | — | CN | disclosed |
| EP-3768760-A1 | FUNCTIONALIZED BIFURAN AND SYNTHESIS THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20210009545-A1 | Functionalized Bifuran and Synthesis Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2021-01-14 | — | — | US | disclosed |
| WO-2020162533-A1 | POLYCARBONATE RESIN COMPOSITION AND OPTICAL LENS USING THIS | 三菱瓦斯化学株式会社 | 2020-08-13 | — | — | WO | disclosed |
| WO-2020116629-A1 | POLYBUTYLENE TEREPHTHALATE RESIN COMPOSITION AND DOUBLE-MOLDED ARTICLE | ポリプラスチックス株式会社 | 2020-06-11 | — | — | WO | disclosed |
| WO-2019182693-A1 | FUNCTIONALIZED BIFURAN AND SYNTHESIS THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-9464166-B2 | Production and use of 3,4' and 4,4'-dimethylbiphenyl isomers | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2016-10-11 | — | — | US | disclosed |
| WO-2015112252-A1 | PRODUCTION AND USE OF 3,4' AND 4,4'-DIMETHYLBIPHENYL ISOMERS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-20150080546-A1 | Production and Use of 3,4' and 4,4'-Dimethylbiphenyl Isomers | EXXONMOBIL CHEMICAL PATENTS INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150080545-A1 | Production and Use of 3,4' and 4,4'-Dimethylbiphenyl Isomers | EXXONMOBIL CHEMICAL PATENTS INC. | 2015-03-19 | — | — | US | disclosed |
| US-8592634-B2 | Process for producing phenol | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20110301387-A1 | Process For Producing Phenol | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-12-08 | — | — | US | disclosed |
| EP-0858444-A4 | CYCLOPENTYL TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1999-12-01 | — | — | EP | disclosed |
| JP-H1130588-A | METHOD FOR DETECTING ION WITH USING CIRCULAR DICHROIC SPECTROCHEMICAL ANALYSIS | SHIMADZU CORP | 1999-02-02 | — | — | JP | disclosed |
| EP-0858444-A1 | CYCLOPENTYL TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-08-19 | — | — | EP | disclosed |
| US-5750549-A | ANTIINFLAMMATORY AGENTS OR ANALGESICS | MERCK & CO., INC. (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1997014671-A1 | CYCLOPENTYL TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080546-A1 | Production and Use of 3,4' and 4,4'-Dimethylbiphenyl Isomers | CYP4B1, HPD, DDT | TSHR 2250/4885TRPA1 1234/4885SLC18A3 2904/4885 |
| US-11926605-B2 | Functionalized bifuran and synthesis thereof | PARG, PUF60, PARP1 | TSHR 3423/4885TRPA1 3896/4885SLC18A3 4854/4885 |
| US-20150080545-A1 | Production and Use of 3,4' and 4,4'-Dimethylbiphenyl Isomers | CYP4B1, HPD, DDT | TSHR 2250/4885TRPA1 1234/4885SLC18A3 2904/4885 |
| US-20110301387-A1 | Process For Producing Phenol | NOX4, CYP2E1, SCO2 | TSHR 3296/4885TRPA1 1603/4885SLC18A3 4273/4885 |
| US-20210009545-A1 | Functionalized Bifuran and Synthesis Thereof | PARG, PUF60, PARP1 | TSHR 3442/4885TRPA1 3871/4885SLC18A3 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.